Sun Pharmaceuticals agreed to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, aiming to expand its women’s health portfolio and strengthen its biosimilar business. Organon’s product base spans more than 70 women’s health and general medicines brands that are commercialized in the U.S. and roughly 140 countries. The companies expect the transaction to close in early 2027. Sun said the combined platform would position it among the top global biopharma players in women’s health and improve geographic reach while also providing access to Organon’s manufacturing network and legacy brands. The deal is also expected to help reduce Organon’s debt burden following its 2021 spinout from Merck, sharpening the financial case for the acquisition alongside strategic portfolio growth.